RT Journal Article
SR Electronic
T1 Application of neighborhood-scale wastewater-based epidemiology in low COVID-19 incidence situations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.07.22276055
DO 10.1101/2022.06.07.22276055
A1 Oh, Chamteut
A1 Zhou, Aijia
A1 O’Brien, Kate
A1 Jamal, Yusuf
A1 Wennerdahl, Hayden
A1 Schmidt, Arthur R
A1 Shisler, Joanna L.
A1 Jutla, Antarpreet
A1 Schmidt, Arthur R
A1 Keefer, Laura
A1 Brown, William M.
A1 Nguyen, Thanh H.
YR 2022
UL http://medrxiv.org/content/early/2022/08/08/2022.06.07.22276055.abstract
AB Wastewater-based epidemiology (WBE), an emerging approach for community-wide COVID-19 surveillance, was primarily characterized at large sewersheds such as wastewater treatment plants serving a large population. Although informed public health measures can be better implemented for a small population, WBE for neighborhood-scale sewersheds is less studied and not fully understood. This study applied WBE to seven neighborhood-scale sewersheds (average population of 1,471) from January to November, 2021. Community testing data showed an average of 0.004% incidence rate in these sewersheds (97% of monitoring periods reported two or fewer daily infections). In 92% of sewage samples, SARS-CoV-2 N gene fragments were below the limit of quantification. We statistically determined 10-2.6 as the threshold of the SARS-CoV-2 N gene concentration normalized to pepper mild mottle virus (N/PMMOV) to alert high COVID-19 incidence rate in the studied sewershed. This threshold of N/PMMOV identified neighborhood-scale outbreaks (COVID-19 incidence rate higher than 0.2%) with 82% sensitivity and 51% specificity. Importantly, neighborhood-scale WBE can discern local outbreaks that would not otherwise be identified by city-scale WBE. Our findings suggest that neighborhood-scale WBE is an effective community-wide disease surveillance tool when COVID-19 incidence is maintained at a low level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Grainger College of Engineering and the JUMP-ARCHES program of OSF Healthcare in conjunction with the University of Illinois.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used only openly available clinical COVID-19 testing data that were originally located at: https://www.c-uphd.org/covid-case-and-testing-data.htmlI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript